FRANKLIN, Tenn., April 13, 2011 /PRNewswire/ -- In the Journal of Advanced Nursing March issue, a comparative research evaluation of five needleless I.V. connectors tested by an independent laboratory showed that the RyMed InVision-Plus® (RYM-5001®) zero displacement connector best protected the intraluminal pathway from bacteria compared with four other commonly used connectors.
The purpose of the study was to evaluate in-vitro differences of colony forming units (CFUs) of four different bacteria (Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli) over four days, using bovine blood, in five needleless connectors (three negative displacement, one positive pressure, and one zero displacement).
"This is a wonderful validation of our product in the world's most read nursing journal focused on advancement of evidence-based nursing," said Dana Wm. Ryan, President & CEO, RyMed Technologies, Inc. "The ultimate goal is to provide the best patient safety no matter if you're a nurse, infection control specialist, family member or parent with a sick child. We believe our product considerably outperformed the other connectors tested in protecting against the potential for bloodstream infections and occlusions as measured by the independent study."
According to the authors, Cynthia Chernecky, Ph. D., RN, FAAN, and Jennifer Waller Ph. D., the data supports use of the least harmful technologies to enhance the safety of intravenous care in all settings and for all patients, although further comparative independent research is needed. "Staff nurses, managers, infection control specialists and vascular access specialists in all settings need to use technologies that invoke the least patient harm," stated the article authors.
The Journal of Advanced Nursing (JAN) is an international, peer-reviewed, scientific journal. JAN contributes to the advancement of evidence-based nursing, midwifery and healthcare by disseminating high quality research and scholarship of contemporary relevance and with potential to advance knowledge for practice, education, management or policy.
About RyMed Technologies, Inc.
Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company's products are designed to help reduce catheter-related bloodstream infections (CR-BSIs) and intraluminal thrombotic catheter occlusions associated with needleless IV connectors. More than 10 years of research and development have gone into InVision-Plus® IV Connector. In January, 2011 the Company introduced the first chlorhexidine+silver ion technology with the new InVision-Plus® CS™. For more information, call (615) 790-8093 or access www.rymedtech.com.
SOURCE RyMed Technologies, Inc.